Belluscura (LSE:BELL) ROCE % : -66.14% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Belluscura ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Belluscura's annualized ROCE % for the quarter that ended in Jun. 2024 was -66.14%.

Belluscura ROCE % Historical Data

The historical data trend for Belluscura's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura ROCE % Chart

Belluscura Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-46.45

-42.02

-34.73

-37.48

-90.46

Belluscura Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial						-38.78	-32.26	-53.14	-106.63	-66.14

Belluscura ROCE % Calculation

Belluscura's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-13.975	/	( ( (19.374 - 2.501)	+	(16.451 - 2.426) )	/ 2 )
	=	-13.975	/	( (16.873	+	14.025)	/ 2 )
	=	-13.975	/	15.449
	=	-90.46 %

Belluscura's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-9.474	/	( ( (16.451 - 2.426)	+	(16.895 - 2.273) )	/ 2 )
	=	-9.474	/	( ( 14.025	+	14.622 )	/ 2 )
	=	-9.474	/	14.3235
	=	-66.14 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Belluscura (LSE:BELL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Belluscura ROCE % Related Terms

Thank you for viewing the detailed overview of Belluscura's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Belluscura Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (LSE:BELL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

9VQ:Germany

Address

15 Fetter Lane, Holborn, London, GBR, EC4A 1BW

Website

https://www.belluscura.com

Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura Headlines

No Headlines